Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Sareum Holdings ( (GB:SAR) ) has issued an announcement.
Sareum Holdings PLC will release its unaudited half-year results for the period ending 31 December 2024 on 25 March 2025. The company will also host a live investor presentation on the same day, open to current and potential shareholders. This event provides an opportunity for stakeholders to engage with the company’s progress and future plans, potentially impacting investor confidence and market positioning.
More about Sareum Holdings
Sareum Holdings PLC is a biotechnology company based in Cambridge, UK, focused on developing next-generation kinase inhibitors for autoimmune diseases and cancer. The company is working on small molecules that modify the JAK kinase family, with lead candidates like SDC-1801 targeting autoimmune diseases such as psoriasis, and SDC-1802 for cancer immunotherapy. Sareum is also advancing SRA737, a Checkpoint kinase 1 inhibitor for cancer treatment.
YTD Price Performance: -50.0%
Average Trading Volume: 342,606
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £16.69M
Learn more about SAR stock on TipRanks’ Stock Analysis page.